Breast Cancer

The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.

With various FDA approvals in the last year alone, nurses must stay up-to-date on the changing treatment landscape of breast cancer to properly treat these patients.

An expert gives an overview of the different treatment approaches for patients with breast cancer that has metastasized to their brain.

After months of debate, the Food and Drug Administration announced that they will be taking action to protect women from breast implant-associated anaplastic large cell lymphoma.

A new surgical method could help treat lymphedema, according to one expert.

By better understanding the subtypes of breast cancer, clinicians can create more personalized and effective treatment plans for patients with breast cancer.

An expert discusses the cardiac toxicity of ABP 980, a trastuzumab biosimilar, in the breast cancer space.

An expert gives an overview of how CDK4/6 inhibitors changed the treatment landscape for patients with metastatic breast cancer.

One expert discusses findings from the TAILORx study.

There is not a major difference in outcomes between whole-breast and partial-breast radiation for some patients with breast cancer.

With a goal of championing the value of patient navigators, Susan G. Komen Greater New York City and NYU Langone have teamed up to provide patients with improved care in Brooklyn through a new patient navigation project.

The Food and Drug Administration (FDA) approved trastuzumab-anns (Kajinti), a biosimilar of trastuzumab (Herceptin) for the treatment of HER2-overexpressing breast cancer, metastatic gastric or gastroesophageal junction adenocarcinoma.

After being treated for breast cancer, nurse practitioners at MSK help survivors transition back to their primary care physicians.

Breast cancer regimens can cause long-term cardiac toxicity in survivors. One trial is delving into why this is the case.

Here are the top 5 Oncology Nursing News stories for May 2019.

The results of genetic testing could have major implications for patients with breast cancer and their families.

Administering chemotherapy to a pregnant woman can be risky, but current guidelines about pregnancy testing are shaky.

The FDA has approved the PI3K inhibitor alpelisib (Piqray) for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

Certain populations are less likely to receive treatment for breast cancer. Nurses should lead a multidisciplinary team to improve that.

This was the first large, randomized clinical trial to show that diet can reduce the risk of dying from breast cancer.

The Food and Drug Administration granted leronlimab a fast track designation for the treatment of patients with metastatic triple-negative breast cancer.

The FDA approved ado-trastuzumab emtansine for the treatment of HER2-positive early breast cancer, after it showed a 50% decrease of disease or death compared with trastuzumab.

After the widespread use of targeted therapies for breast cancer treatment, there was a wider gap in mortality rates between black and white women with the disease.

Although Minority Health Awareness Month is drawing to an end, the fight for equity in healthcare isn’t over.

Diabetes may be a risk factor for increased symptoms among breast cancer survivors, highlighting the need for interventions to control the disease, according to secondary analysis results presented at the ONS 44th Annual Congress.